Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Tanzina Haque"'
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 18, p 6721 (2020)
Background: The limitations of conventional treatment modalities in cancer, especially in breast cancer, facilitated the necessity for developing a safer drug delivery system (DDS). Inorganic nano-carriers based on calcium phosphates such as hydroxya
Externí odkaz:
https://doaj.org/article/9820797e8fa0497295daff46e22d3582
Autor:
Sheikh Tanzina Haque, Md. Emranul Karim, Syafiq Asnawi Zainal Abidin, Iekhsan Othman, Mark M. Banaszak Holl, Ezharul Hoque Chowdhury
Publikováno v:
Nanomaterials, Vol 10, Iss 5, p 834 (2020)
Breast cancer is the abnormal, uncontrollable proliferation of cells in the breast. Conventional treatment modalities like chemotherapy induce deteriorating side effects on healthy cells. Non-viral inorganic nanoparticles (NPs) confer exclusive chara
Externí odkaz:
https://doaj.org/article/7648d5916cea473a9bcae8a233926d93
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 18
International Journal of Molecular Sciences, Vol 21, Iss 6721, p 6721 (2020)
Volume 21
Issue 18
International Journal of Molecular Sciences, Vol 21, Iss 6721, p 6721 (2020)
Background: The limitations of conventional treatment modalities in cancer, especially in breast cancer, facilitated the necessity for developing a safer drug delivery system (DDS). Inorganic nano-carriers based on calcium phosphates such as hydroxya
Publikováno v:
Bulletin of Faculty of Pharmacy, Cairo University, Vol 56, Iss 1, Pp 34-38 (2018)
Petroleum ether, ethyl acetate and methanol extracts of the stem bark of Albizia lebbeck and Acacia nilotica was investigated for antimicrobial, antioxidant and cytotoxicity assay. The powdered stem bark was extracted successively with petroleum ethe
Publikováno v:
Current Drug Delivery. 15:485-496
Background Delivery of conventional small molecule drugs and currently evolving nucleic acid-based therapeutics, such as small interfering RNAs (siRNAs) and genes, and contrast agents for high resolution imaging, to the target site of action is highl
Autor:
Ana Garcia-Diaz, Adele L. McCormick, Margaret A. Johnson, Colette Smith, Sanjay Bhagani, Daniel P. Webster, Luke Moynihan, Malcolm J Macartney, Tanzina Haque, Alison Rodger
Publikováno v:
Antiviral Therapy. 20:361-363
Autor:
Adele L. McCormick, Malcolm J Macartney, Michael Jacobs, Amanda Tavares, Wendy Labbett, Tanzina Haque, William Rosenberg, Giorgio Calisti, Geoffrey Dusheiko
Publikováno v:
SpringerPlus
Single nucleotide polymorphisms (SNPs) in the IL28B gene were shown to have limited utility in predicting response to telaprevir and boceprevir in treatment of chronic HCV infection in clinical trials. Data outside of the clinical trial setting are l
Autor:
Adele L. McCormick, Daniel P. Webster, Colette Smith, Wendy Labbett, Malcolm J Macartney, Dianne Irish, Tanzina Haque, Ikran Abdi-Abshir
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 66
Background Hepatitis C virus (HCV) genotyping is required for tailoring the dose and duration of antiviral therapy, predicting virological response rates, and selecting future treatment options. Objective To establish whether baseline genotypes, perf
Autor:
Margaret Johnson, Tim Conibear, Keir E J Philip, Daniel P. Webster, Malcolm J Macartney, Tanzina Haque, Neal Marshall, Colette J Smith
Publikováno v:
International journal of STDAIDS. 27(7)
HIV co-receptor tropism determination is essential before prescribing the CCR5 antagonist maraviroc. British HIV Association guidelines suggest tropism testing may remain valid for only 90 days in antiretroviral-naïve patients. We aimed to determine
Autor:
Michael Jacobs, Sudeep Tanwar, Adele L. McCormick, Clare Booth, Ana Garcia-Diaz, Carmen Velazquez, Wendy Labbett, William Rosenberg, Geoff Dusheiko, Dianne Irish, Simon H. Bridge, Tanzina Haque, Malcolm J Macartney, Colette J. Smith, P M Trembling
Publikováno v:
Antiviral research. 105
The use of triple-therapy, pegylated-interferon, ribavirin and either of the first generation hepatitis C virus (HCV) protease inhibitors telaprevir or boceprevir, is the new standard of care for treating genotype 1 chronic HCV. Clinical trials have